Literature DB >> 22009246

Risk factors: Race, renal disease and albuminuria.

Barry I Freedman, Donald W Bowden.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22009246      PMCID： PMC3280425          DOI： 10.1038/nrneph.2011.154

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

Review 2.  Genetics of kidney failure and the evolving story of APOL1.

Authors:  David J Friedman; Martin R Pollak
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

3.  The APOL1 gene and allograft survival after kidney transplantation.

Authors:  A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman
Journal:  Am J Transplant       Date:  2011-04-12       Impact factor: 8.086

4.  Albuminuria and racial disparities in the risk for ESRD.

Authors:  William M McClellan; David G Warnock; Suzanne Judd; Paul Muntner; Reshma Kewalramani; Mary Cushman; Leslie A McClure; Britt B Newsome; George Howard
Journal:  J Am Soc Nephrol       Date:  2011-08-25       Impact factor: 10.121

5.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

Review 6.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

7.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group.

Authors:  W G Walker; J D Neaton; J A Cutler; R Neuwirth; J D Cohen
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

8.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group.

Authors:  N B Shulman; C E Ford; W D Hall; M D Blaufox; D Simon; H G Langford; K A Schneider
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

9.  Ethnic differences in the relationship between albuminuria and calcified atherosclerotic plaque: the African American-diabetes heart study.

Authors:  Jasmin Divers; Lynne E Wagenknecht; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Jianzhao Xu; Carl D Langefeld; Barry I Freedman
Journal:  Diabetes Care       Date:  2009-10-13       Impact factor: 19.112
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.